About us
MSBase Foundation & MGBase
Learn more about us, and our mission, vision, and values.
About MGBase Registry
The MGBase Registry, launched in Australia in 2021, is the first global observational registry dedicated to patients diagnosed with Myasthenia Gravis (MG). Since its inception, the registry has grown exponentially with expanding global reach.
MGBase generates valuable real-world clinical evidence, including insights into treatment outcomes, safety profiles, and disease prognostic markers. This information will support improved clinical practice and patient care worldwide.
MGBase is owned, operated, and supported by the MSBase Foundation Ltd, an independent, not-for-profit company, registered in Australia. The Foundation also manages the MSBase Registry. Governance of the MSBase Foundation is provided by a Board of Directors. In addition, a dedicated global MGBase Scientific Leadership Group (SLG) offers strategic guidance on research priorities and scientific direction for the registry.
Membership to the registry is open to practising neurologists and their healthcare teams worldwide. The MSBase Foundation provides a globally accepted, GDPR-compliant suite of governance documents that details terms of participation and enables secure, lawful international data sharing. In addition, the Foundation has achieved ISO/IEC 27001:2022 certification of its Information Security Management System, covering the operations of its digital infrastructure.
Each MGBase centre is led by a Principal Investigator (PI) who is responsible for their centre's participation in the registry, ensuring compliance with the MSBase Foundation governance framework in addition to their local laws and regulations. MGBase centres gain free access to iMed Web, an intuitive, clinician-focused platform for capturing and visualising MG patient data. This platform is used to contribute pseudonymised MG patient data to the registry and supports improved clinical decision-making and evidence-based insights. In turn, PIs can request access to the global database for research purposes, to advance collaborative epidemiological and outcomes research and ultimately lead to improved patient outcomes.
MGBase has provided an efficient electronic database of capturing ur clinical observations and treatment responses in the MG clinic. It has the potential of allowing 'real world' global comparisons in treatment approaches, and providing exposure to Pharma of previously neglected research-oriented clinics with diverse patient populations.
Jeannine Heckmann, South Africa
